BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, September 22, 2023
Home » Blogs » BioWorld Perspectives » Kudos to Four Little Biotechs Doing Cool Science

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Kudos to Four Little Biotechs Doing Cool Science

Sep. 26, 2011
By Trista Morrison
No Comments

I recognize that while a lot of you busy biotech folk subscribe to BioWorld Today, I am probably one of the only people who actually reads every single word of the paper every single day.

In doing so, I often come across really cool companies doing really cool stuff that you might have missed if you were just scanning the headlines for news related to one particular indication or another. So here’s a shout-out to a few of the coolest little companies I’ve stumbled on recently:

ŸKingdoms Cross Station: NovaDigm Therapeutics Inc. just popped on the radar at ICAAC with the first vaccine shown to provide protection against pathogens from two kingdoms: fungi and bacteria. The NDV-3 vaccine is in Phase I development to prevent diseases caused by Candida and Staphylococcus aureus.

ŸProgrammable Immunity: Altermune Technologies LLC just raised $7 million in seed funding to support its work on programmable immunity. Founded by Nobel laureate and polymerase chain reaction inventor Kary Mullis, the firm is pursuing the theory that the immune system's own antibodies – ubiquitous antibodies that typically are not charged with fighting infection – can be recruited and directed against a desired pathogen.

ŸCancer Prevention: As its name indicates, Cancer Prevention Pharmaceuticals Inc. is trying to stop benign tumors from becoming malignant. Jumping off of work done in academia and at other firms, CPP is already poised for pivotal trials.

ŸWhere No Mab’s Gone Before: Permeon Biologics Inc. is using a class of natural proteins, dubbed intraphilins, to deliver biological molecules inside of cells. The approach could open up thousands of targets previously inaccessible to biologics.

Know of a biotech doing something super-cool? Tell us about it at newsdesk@bioworld.com

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 21, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing